Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation

Thoracic and Cardiovascular Surgeon

Volumn 60, Issue 1, 2012, Pages 26-34

  Hefke, T ^a   Zittermann, A ^a   Fuchs, U ^a   Schulte Eistrup, S ^a   Gummert, J F ^a   Schulz, U ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

bosentan; cardiac transplantation; end stage heart failure; endothelin 1; mortality; pulmonary hypertension; survival

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PHOSPHODIESTERASE III INHIBITOR;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DEFIBRILLATOR; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PACEMAKER; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCORING SYSTEM; SIDE EFFECT; SURVIVAL RATE; TRANSPULMONARY GRADIENT; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; FEMALE; GERMANY; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PULMONARY ARTERY; RECEPTORS, ENDOTHELIN; RETROSPECTIVE STUDIES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84857375082     PISSN: 01716425     EISSN: 14391902     Source Type: Journal    
DOI: 10.1055/s-0030-1250726     Document Type: Article

References (19)

1. Gali N, Hoeper MM, Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J: 2009; 30 2493 2537
2. Moreas DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure-The role of the endothelium in pathophysiology and management. Circulation: 2000; 102 1718 1723
3. Grigioni F, Potena L, Gali N., et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant: 2006; 25 1241 1246 (Pubitemid 44528289)
4. Mylona P, Cleland JGF. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Fail: 1999; 1 197 200 (Pubitemid 30186712)
5. Mehra MR, Kobashigawa J, Starling R., et al. Listing criteria for heart transplantation: international society for heart and lung transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant: 2006; 25 1024 1042 (Pubitemid 44311532)
6. Addonizio LJ, Gersony WM, Robbins RC., et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation: 1987; 76 V52 V55
7. Gude E, Simonsen S, Geiran OR., et al. Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics. J Heart Lung Transplant: 2010; 29 216 223
8. Hoppe J-D, Schreiber H-L. Richtlinien zur Organtransplantation gemäß 16 Transplantationsgesetz. Dtsch Arztebl: 2000; 97 A-396 A-411
9. Cowburn PJ, Cleland JGF. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J: 2001; 22 1772 1784 (Pubitemid 32929112)
10. Kiowski W, Sütsch G, Hunziker P., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet: 1995; 346 732 736
11. Pacher R, Stanek M, Hülsmann M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Amer Coll Cardiol: 1996; 27 633 641 (Pubitemid 26081922)
12. Schulz U, Tenderich G, Schulte-Eistrup S., et al. Bosentan in pulmonary hyertension secondary to left heart failure. Curr Med Res Opin: 2007; 23 S77 S82 (Pubitemid 47169076)
13. Ghio S, Gavazzi A, Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol: 2001; 37 183 188 (Pubitemid 32051736)
14. Mathews L. Paradigm shift in hemodynamic monitoring. The Internet Journal of Anesthesiology: 2007; 11 2
15. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Result of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J: 2007; 30 338 344 (Pubitemid 47194187)
16. Gali N, Rubin LJ, Hoeper MM., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trail. Lancet: 2008; 371 2093 2100
17. Rubin LJ, Badesch DB, Barst RJ., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med: 2002; 346 896 903 (Pubitemid 34984638)
18. Kaluski E, Cotter G, Leitman M., et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology: 2008; 109 273 280 (Pubitemid 351328923)
19. Moreas DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure-The role of the endothelium in pathophysiology and management. Circulation: 2000; 102 1718 1723